R&D tax credit included in $700 billion bailout plan
This article was originally published in The Gray Sheet
Executive Summary
Extension of research and development tax provisions favored by the device industry is attached to the $700 billion Emergency Economic Stabilization Act of 2008, passed by the House and Senate last week and signed by President Bush Oct. 3 ("1The Gray Sheet" Dec. 10, 2007, p. 14)
You may also be interested in...
R&D Tax-Credit Extension Goes Down To The Wire
Device lobbyists are joining a year-end push for an extension of a soon-to-expire tax credit for companies engaged in research and development, but opportunities are running out
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.